Looking real good so far.
DMSI Develops Working Model of Antiseptic Wand Monday February 6, 7:18 pm ET In Talks With U.S. Army to Build Battlefield Version WEST CONSHOHOCKEN, Pa., Feb. 6 /PRNewswire-FirstCall/ -- Dermisonics, Inc. (OTC Bulletin Board: DMSI.OB - News), a pioneer in the development of ultrasonic transdermal drug-delivery technologies, announced today that it has completed the first working model of its A-Wand antiseptic delivery system and is in talks with the Army Institute of Surgical Research under the Combat Casualty Care Research Program to develop a battlefield version.
The A-Wand (TM) is a handheld, portable, ultrasonic wand device for applying antiseptic solutions to cuts, abrasions and wounds with a replaceable Patch-Cap (TM), which holds up to 40 ml of antiseptic solution. It uses alternating ultrasonic waveforms to enlarge the diameter of the skin pores enabling antiseptics to permeate through the skin (Stratum Corneum) into the dermis through the sweat pores. Attacks Critical Problem of Infections in Wounded Soldiers -- Infection is a major, potentially lethal, battlefield hazard for wounded soldiers before they can receive full medical treatment in a hospital. The Medic on the scene applies antiseptic and bandages the wound but the antiseptic only affects the outermost layers of the damaged tissue. Infection frequently results and is a major cause of amputations. The A-Wand Encapsulates the Wounded Area with Antiseptic -- The A-Wand would be used by Medics in the field, by Mash units and for follow-up wound care to significantly reduce this hazard. Through the use of the A-Wand's ultrasound system, the antiseptic solution is "pushed" to the deeper tissue where it can more effectively fight infection by surrounding and encapsulating the wounded area with antiseptic. It also has the added advantage of being able to penetrate scared tissue without damaging this basic body defense system. Technology inventor and Dermisonics Executive Vice-President Bruce Redding commented, "The A-Wand represents a huge opportunity for Dermisonics and the various patients who could benefit from increased infection-resistant technologies. Dermisonics especially is pleased by the response from the US Army and we hope this technology finds acceptance in the field as soon as possible" The Next Generation in the $1.2 Billion Wound Care Market -- The Company believes the A-Wand will represent a significant shift in wound-care medical science and will fundamentally change the $1.2 billion wound-care market. Industry Opportunity and Receptivity -- As a harbinger of its immediate industry impact, the Company has already received, in addition to the military, strong indications of interest from major companies in the pharmaceutical and hospital fields.
__________________________________________________
Gotta do some more research too!
AI
